A surgeon weighs the question more patients are raising as semaglutide and tirzepatide reshape weight management options.
Recap by typeshit. Post by @drsamyelvertonmd on Instagram.
TIKR points to retatrutide, due for filing in early 2027, and says a pending Seventh Circuit ruling on whether it counts as a biologic could decide 5 vs 12 years of exclusivity.
She lost 7 kilos in her first month, regained it during a month-long break, and now says she's eating more and gaining in week two back.
A shared report on doctors turning to GLP-1 medications for weight loss in some kids. Details are thin, so tap through for the full story.
The author, who holds Novo shares, cites Morgan Stanley's $190 billion obesity market forecast for 2035 and an NIH-funded mouse study on aging.
The physician-led longevity service lists GLP-1 management and peptide therapy among its offerings and opens first inside Everhaus Las Vegas in early 2027.
A Harvard and Copenhagen review found 43 percent of users eat too little protein, and a Northwestern study saw deficiencies in nearly one in six teens.
Loading…